Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.30 -6.5%	$1.30	$1.05 ▼ $10.16	$40.90M	1.65	418,123 shs	429,270 shs
COEP Coeptis Therapeutics	$13.57 -7.4%	$9.75	$2.31 ▼ $14.70	$47.63M	-0.59	83,368 shs	57,736 shs
LGVN Longeveron	$0.83 +2.3%	$1.34	$0.63 ▼ $2.86	$12.57M	0.23	509,180 shs	966,413 shs
LVTX LAVA Therapeutics	$1.52	$1.40	$0.85 ▼ $2.09	$39.99M	0.5	205,787 shs	52,285 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.96%	+13.01%	+2.96%	+11.20%	-81.71%
COEP Coeptis Therapeutics	+4.87%	+32.46%	+37.17%	+51.66%	+262.80%
LGVN Longeveron	+6.45%	+16.35%	-46.78%	-39.63%	-65.57%
LVTX LAVA Therapeutics	0.00%	0.00%	+7.04%	+15.15%	-15.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.7148 of 5 stars	3.5	3.0	2.4	1.7	0.6
COEP Coeptis Therapeutics	0.5158 of 5 stars	0.0	3.0	2.0	1.7	0.0
LGVN Longeveron	3.6769 of 5 stars	3.5	5.0	2.9	1.7	1.3
LVTX LAVA Therapeutics	2.1988 of 5 stars	3.0	5.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.57	1,251.65% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
LGVN Longeveron	3.00	Buy	$7.25	775.82% Upside
LVTX LAVA Therapeutics	2.00	Hold	$2.69	76.64% Upside

Current Analyst Ratings Breakdown

Latest LGVN, LVTX, COEP, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00
8/14/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
LGVN Longeveron	$2.39M	5.26	N/A	N/A	$1.47 per share	0.56
LVTX LAVA Therapeutics	$11.98M	3.34	N/A	N/A	$1.06 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.25	N/A	N/A	N/A	N/A	-50.78%	-46.08%	N/A
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-216.96%	-113.00%	N/A
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-894.40%	-95.91%	-79.69%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.05	N/A	N/A	N/A	N/A	-106.29%	-38.24%	8/19/2025 (Estimated)

Latest LGVN, LVTX, COEP, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/13/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.55	+$0.02	-$0.55	N/A	N/A
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	10.31	10.31
COEP Coeptis Therapeutics	0.02	0.82	0.82
LGVN Longeveron	N/A	3.43	3.43
LVTX LAVA Therapeutics	N/A	10.78	10.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
COEP Coeptis Therapeutics	13.88%
LGVN Longeveron	10.01%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	8.50%
COEP Coeptis Therapeutics	24.25%
LGVN Longeveron	11.20%
LVTX LAVA Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.46 million	28.78 million	Not Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable

LGVN, LVTX, COEP, and ACRV Headlines

Recent News About These Companies

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Average Rating of "Hold" by Brokerages

August 10, 2025 | americanbankingnews.com

LAVA Therapeutics (NASDAQ:LVTX) Stock Rating Lowered by Jefferies Financial Group

August 8, 2025 | americanbankingnews.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

August 8, 2025 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

August 7, 2025 | prnewswire.com

Jefferies Downgrades LAVA Therapeutics N.V. (LVTX)

August 5, 2025 | msn.com

LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty

August 4, 2025 | msn.com

XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics

August 4, 2025 | msn.com

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

August 4, 2025 | businesswire.com

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

June 13, 2025 | tipranks.com

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 15, 2025 | finanznachrichten.de

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 14, 2025 | globenewswire.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock News

April 16, 2025 | gurufocus.com

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency

April 16, 2025 | quiverquant.comQ

LAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...

April 16, 2025 | gurufocus.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

April 16, 2025 | globenewswire.com

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

March 29, 2025 | markets.businessinsider.com

LAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99M

March 28, 2025 | seekingalpha.com

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, LVTX, COEP, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.30 -0.09 (-6.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1.35 +0.05 (+3.85%)

As of 04:43 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Coeptis Therapeutics NASDAQ:COEP

$13.57 -1.08 (-7.37%)

Closing price 03:59 PM Eastern

Extended Trading

$13.51 -0.06 (-0.44%)

As of 04:10 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Longeveron NASDAQ:LGVN

$0.83 +0.02 (+2.32%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 -0.03 (-3.12%)

As of 05:30 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

LAVA Therapeutics NASDAQ:LVTX

$1.52 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.53 +0.01 (+0.66%)

As of 04:10 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time